Miriam Bennett
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Miriam Bennett has a total of 67 co-authors. Here are the top co-authors by number of shared publications:
Angela Simpson
Manchester University NHS Foundation Trust, United Kingdom
8 shared publications- Jiakai Wu
Lydia Becker Institute of Immunology and Inflammation University of Manchester Manchester UK
4 shared publications Alexander G. Mathioudakis
Division of Immunology, Immunity to Infection and Respiratory Medicine, University of Manchester, Manchester, United Kingdom; Department of Respiratory Medicine and Allergy, Manchester University NHS Foundation Trust, Manchester, United Kingdom
3 shared publicationsChiara Tontini
Division of Immunology, Immunity to Infection and Respiratory Medicine, University of Manchester, Manchester, United Kingdom
3 shared publicationsClare Murray
The University of Manchester Division of Infection Immunity and Respiratory Medicine
3 shared publicationsClare S. Murray
Manchester University NHS Foundation Trust, United Kingdom
3 shared publications
Latest Publications
- 14 September 2024
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 64 (suppl 68) , PA4014
Clinical phenotyping in untreated paediatric and adult asthma: a systematic review
Asthma affects around 8% of the global population. Identifying groups based on clinical characteristics (phenotypes) may improve diagnostic accuracy and drive targeted management to alter the disease trajectory. To date, most phenotyping has focused on severe asthma. Aim: Systematic review of the literature on phenotyping in untreated paediatric and adult asthma. Methods: Registered with PROSPERO (CRD42023483258). Embase, Medline, CINHAL and Cohrane databases searched on 29/12/2023 with terms: asthma* ADJ2 (naïve, untreated, “new diagnos*”, not treat*” OR) AND (endotype*, phenotyp*, “treatable trait*” OR). No limits on language, age or study type. Inclusion criteria: comparing untreated asthma clinical phenotypes. Exclusion criteria: Use of regular asthma therapy. Reported according to PRISMA using GRADE and ROBINS-I tools. Results: 467 records were identified through database searches; 167 duplicates were removed and 350 abstracts independently reviewed; 205 for full text review. 195 did not report data on or compare untreated asthma phenotypes; 10 were identified for analysis. Data on 1683 participants; minimum age 6, majority adults. Four studies used data-driven methods to identify phenotypes and six used non data-driven methods. Phenotypes were driven largely by baseline characteristic selection which varied widely across studies. Lung physiology differentiated data-driven phenotypes while atopy, fractional exhaled nitric oxide (FeNO) and blood eosinophilia differentiated non data-driven phenotypes. Conclusion: Future work looking at untreated asthma phenotyping should justify initial characteristic selection and as a minimum include lung physiology, atopy, blood eosinophilia and FeNO.
- 14 September 2024
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 64 (suppl 68) , PA4014
Clinical phenotyping in untreated paediatric and adult asthma: a systematic review
Asthma affects around 8% of the global population. Identifying groups based on clinical characteristics (phenotypes) may improve diagnostic accuracy and drive targeted management to alter the disease trajectory. To date, most phenotyping has focused on severe asthma. Aim: Systematic review of the literature on phenotyping in untreated paediatric and adult asthma. Methods: Registered with PROSPERO (CRD42023483258). Embase, Medline, CINHAL and Cohrane databases searched on 29/12/2023 with terms: asthma* ADJ2 (naïve, untreated, “new diagnos*”, not treat*” OR) AND (endotype*, phenotyp*, “treatable trait*” OR). No limits on language, age or study type. Inclusion criteria: comparing untreated asthma clinical phenotypes. Exclusion criteria: Use of regular asthma therapy. Reported according to PRISMA using GRADE and ROBINS-I tools. Results: 467 records were identified through database searches; 167 duplicates were removed and 350 abstracts independently reviewed; 205 for full text review. 195 did not report data on or compare untreated asthma phenotypes; 10 were identified for analysis. Data on 1683 participants; minimum age 6, majority adults. Four studies used data-driven methods to identify phenotypes and six used non data-driven methods. Phenotypes were driven largely by baseline characteristic selection which varied widely across studies. Lung physiology differentiated data-driven phenotypes while atopy, fractional exhaled nitric oxide (FeNO) and blood eosinophilia differentiated non data-driven phenotypes. Conclusion: Future work looking at untreated asthma phenotyping should justify initial characteristic selection and as a minimum include lung physiology, atopy, blood eosinophilia and FeNO.
- Open Access
- 5 September 2024
- Published by Elsevier in eClinicalMedicine
- Vol. 76, 102813
Asthma diagnosis: a comparison of established diagnostic guidelines in adults with respiratory symptoms
- 5 September 2024
- Published by Elsevier in eClinicalMedicine
- Vol. 76, 102813
Open AccessAsthma diagnosis: a comparison of established diagnostic guidelines in adults with respiratory symptoms
- 6 March 2024
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 12 (3) , 802-803
Reply to “The use of basophil activation tests (BATs) in the diagnosis of penicillin allergy”
- 6 March 2024
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 12 (3) , 802-803
Reply to “The use of basophil activation tests (BATs) in the diagnosis of penicillin allergy”
- Open Access
Performance characteristics of basophil activations tests for diagnosing penicillin allergy: a meta-analysis
Background: Approximately 10% of the global population identify themselves as penicillin allergic, yet 90% are not truly allergic and could safely tolerate penicillin. There is no simple way to identify these people. Current in vitro diagnostics include specific immunoglobulin E, sIgE (with a sensitivity of 19% and specificity of 97%) and basophil activation testing (BAT) with undefined sensitivity and specificity. Objective: To define the sensitivity and specificity of BAT in the diagnosis of penicillin allergy Methods: PubMed and EMBASE searched from inception to 04/02/2023 for original studies evaluating the performance characteristics of basophil activation test for penicillin allergy in adults. Study selection, data extraction, risk of bias, assessment with QUADAS-2 tool, certainty assessment with GRADE methodology were performed independently, in duplicate. Meta-analysis was performed using Reitsma methodology. Results: Twenty-two studies fulfilled the inclusion criteria. Twelve used the same positive threshold giving a summary point sensitivity 51% (95% CI, 46%-56%) and specificity 89% (95% CI, 85%-93%). Significant risk of bias was identified due to patient selection. GRADE certainty of evidence rated sensitivity “very low” due to imprecision and specificity as “low”. There was great heterogeneity in methods used. Use of 1000 basophils per test did not improve performance above 500 basophils. Conclusion: BAT sensitivity is highly variable across studies and remains too low to be considered as a routine element of clinical practice. BAT specificity is not as good as sIgE in penicillin allergy diagnosis. Significant further work is required in this field before clinical application of BAT in routine practice.
Open AccessPerformance characteristics of basophil activations tests for diagnosing penicillin allergy: a meta-analysis
Background: Approximately 10% of the global population identify themselves as penicillin allergic, yet 90% are not truly allergic and could safely tolerate penicillin. There is no simple way to identify these people. Current in vitro diagnostics include specific immunoglobulin E, sIgE (with a sensitivity of 19% and specificity of 97%) and basophil activation testing (BAT) with undefined sensitivity and specificity. Objective: To define the sensitivity and specificity of BAT in the diagnosis of penicillin allergy Methods: PubMed and EMBASE searched from inception to 04/02/2023 for original studies evaluating the performance characteristics of basophil activation test for penicillin allergy in adults. Study selection, data extraction, risk of bias, assessment with QUADAS-2 tool, certainty assessment with GRADE methodology were performed independently, in duplicate. Meta-analysis was performed using Reitsma methodology. Results: Twenty-two studies fulfilled the inclusion criteria. Twelve used the same positive threshold giving a summary point sensitivity 51% (95% CI, 46%-56%) and specificity 89% (95% CI, 85%-93%). Significant risk of bias was identified due to patient selection. GRADE certainty of evidence rated sensitivity “very low” due to imprecision and specificity as “low”. There was great heterogeneity in methods used. Use of 1000 basophils per test did not improve performance above 500 basophils. Conclusion: BAT sensitivity is highly variable across studies and remains too low to be considered as a routine element of clinical practice. BAT specificity is not as good as sIgE in penicillin allergy diagnosis. Significant further work is required in this field before clinical application of BAT in routine practice.
- Open Access
- 7 November 2023
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 12 (3) , 714-723.e5
Performance Characteristics of Basophil Activation Tests for Diagnosing Penicillin Allergy: A Meta-Analysis
- 7 November 2023
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 12 (3) , 714-723.e5
Open AccessPerformance Characteristics of Basophil Activation Tests for Diagnosing Penicillin Allergy: A Meta-Analysis
- Open Access
- 22 February 2023
- Published by Wiley
Amoxicillin induced mast cell degranulation mediated by FcεRI specific IgG: a new insight to beta-lactam allergy
Amoxicillin induced mast cell degranulation mediated by FcεRI specific IgG: a new insight to beta-lactam allergy To the editor,Immediate drug hypersensitivity reactions (IDHR) to beta-lactams (BL), referred to here as beta-lactam allergy (BLA), is defined as the development of symptoms such as urticaria and bronchospasm within one hour of beta-lactam exposure (1). Classical Type 1 immunoglobulin E (IgE)-mediated allergy describes a response which occurs within minutes of allergen exposure in a previously sensitised person. It has therefore been widely accepted that BLA is mediated by beta-lactam specific IgE (BL-sIgE) (1). In other Type 1 IgE driven allergies, such as food allergy, sIgE to major allergen components can be shown to be highly specific (2, 3). However, for BLA, BL-sIgE has poor specificity, suggesting alternative mechanisms might be involved (4).Type 1 IgE mediated reactions are mainly mediated by basophils and mast cells (MCs). Previous studies have demonstrated the use of the basophil activation test (BAT) in predicting BLA, with European allergy guidance stating that BAT can aid BLA diagnosis (5). However, BAT requires fresh whole blood which is not ideal for in depth mechanistic exploration.In an in vitro BLA model using human progenitor derived MCs, we have shown that MCs sensitised with serum from a patient with confirmed BLA, demonstrated amoxicillin (AMX) induced degranulation (CD63+ positivity) after 30 minutes of stimulation with AMX (Figure 1B). In contrast, sensitisation with serum from a non-BLA control demonstrated no response (Figure 1C).The mechanism of degranulation from the BLA model is very different from the classical IgE-mediated Type 1 degranulation such as that seen in food and inhalant allergy (6). In our in vitro model of classical IgE-mediated Type 1 degranulation, sIgE binds to FcɛRI with high affinity which is not disturbed by pipetting and washing (6). In our BLA model, BLA serum sensitized MCs have a much weaker degranulation and can easily lose their response to beta-lactam stimulation under physical disturbance (Figure 1A).We hypothesised that FcɛRI was involved in the degranulation process in BLA, not through the high affinity binding of IgE, but instead through IgG binding. We produced a recombinant fragment representing the extracellular portion of the FcɛRI receptor alpha chain, which is mainly responsible for antibody binding. When added to the serum, this fragment binds and neutralizes FcɛRI-specific antibody—IgE and IgG, by preventing them binding to the cells. BLA serum was treated with increasing concentrations of the FcɛRI fragments and then added to the MCs for sensitization. After stimulating the sensitized MCs using AMX, we observed a dosage-dependent decrease of MCs degranulation, indicating direct involvement of the FcɛRI in the degranulation process of BLA (Figure 2A).To investigate whether degranulation was mediated by IgE, we neutralized serum IgE by adding omalizumab before MC sensitisation. This showed no impact on the AMX induced degranulation (Figure 2A). In contrast, omalizumab inhibited MC degranulation in a classical IgE model, using pooled serum from cat allergic patients stimulated with cat allergen (Figure 2B).To determine whether FcεRI-specific IgG is functionally responsible for the AMX induced MCs degranulation, we isolated IgG from BLA serum using IgG-depletion spin columns. MCs sensitized with the IgG-only fraction showed no response to anti-IgE, but retained a strong response to AMX (Figure 2B). In comparison, in the IgG-depleted serum fraction (~60% IgG removed), we observed a strong degranulation to anti-IgE stimulation but a weakened response to AMX (Figure 2C).A limitation of this preliminary work is it used serum from only one BLA patient.In summary, we developed a cell model for BLA using in vitrodifferentiated human MCs. This BLA model has demonstrated the involvement of FcεRI-specific IgG in mediating AMX-induced MCs degranulation. The results are worthy of further investigation in a larger patient cohort.Word Count 599Figure legend ( Word count 98 and 98 respectively, max 100)Figure 1. Demonstration of in vitro BLA model using MCs derived from human progenitor cells. A) After washing the sensitized MCs with phosphate buffered saline (PBS), different cells responsiveness to AMX and anti-IgE. B) When adding the AMX in the presence of BL IDHR serum, cell degranulation was observed. C) No degranulation was observed from AMX stimulation when serum from a non-BL IDHR subject was used. D) Treatment of AMX in the absence of serum showed a mild increase of CD63 compared to cells without stimulation, Percentage CD63+ cells is shown in the box. Representative figures from three independent experiments.Figure 2. Investigating the role of FcεRI-specific IgG in BLAin vitro model A) the BLA in vitro model, B) classical type I IgE cat allergy model. AMX or cat allergen induced degranulation was quantified on MCs sensitized with single BLA or pooled cat allergic subject serum pre-treated with recombinant FcεRI alpha chain fragment or omalizumab. C) BLA in vitro model; MCs sensitized with either IgG-depleted serum fraction or IgG-only fraction. Sensitised MCs were stimulated with anti-IgE, AMX or media control. Histogram demonstrating fluorescence intensity of CD63 expression on MCs surface. Mean ±SD. *=p<0.05 from three independent experiments, NS=not significant.
- 22 February 2023
- Published by Wiley
Open AccessAmoxicillin induced mast cell degranulation mediated by FcεRI specific IgG: a new insight to beta-lactam allergy
Amoxicillin induced mast cell degranulation mediated by FcεRI specific IgG: a new insight to beta-lactam allergy To the editor,Immediate drug hypersensitivity reactions (IDHR) to beta-lactams (BL), referred to here as beta-lactam allergy (BLA), is defined as the development of symptoms such as urticaria and bronchospasm within one hour of beta-lactam exposure (1). Classical Type 1 immunoglobulin E (IgE)-mediated allergy describes a response which occurs within minutes of allergen exposure in a previously sensitised person. It has therefore been widely accepted that BLA is mediated by beta-lactam specific IgE (BL-sIgE) (1). In other Type 1 IgE driven allergies, such as food allergy, sIgE to major allergen components can be shown to be highly specific (2, 3). However, for BLA, BL-sIgE has poor specificity, suggesting alternative mechanisms might be involved (4).Type 1 IgE mediated reactions are mainly mediated by basophils and mast cells (MCs). Previous studies have demonstrated the use of the basophil activation test (BAT) in predicting BLA, with European allergy guidance stating that BAT can aid BLA diagnosis (5). However, BAT requires fresh whole blood which is not ideal for in depth mechanistic exploration.In an in vitro BLA model using human progenitor derived MCs, we have shown that MCs sensitised with serum from a patient with confirmed BLA, demonstrated amoxicillin (AMX) induced degranulation (CD63+ positivity) after 30 minutes of stimulation with AMX (Figure 1B). In contrast, sensitisation with serum from a non-BLA control demonstrated no response (Figure 1C).The mechanism of degranulation from the BLA model is very different from the classical IgE-mediated Type 1 degranulation such as that seen in food and inhalant allergy (6). In our in vitro model of classical IgE-mediated Type 1 degranulation, sIgE binds to FcɛRI with high affinity which is not disturbed by pipetting and washing (6). In our BLA model, BLA serum sensitized MCs have a much weaker degranulation and can easily lose their response to beta-lactam stimulation under physical disturbance (Figure 1A).We hypothesised that FcɛRI was involved in the degranulation process in BLA, not through the high affinity binding of IgE, but instead through IgG binding. We produced a recombinant fragment representing the extracellular portion of the FcɛRI receptor alpha chain, which is mainly responsible for antibody binding. When added to the serum, this fragment binds and neutralizes FcɛRI-specific antibody—IgE and IgG, by preventing them binding to the cells. BLA serum was treated with increasing concentrations of the FcɛRI fragments and then added to the MCs for sensitization. After stimulating the sensitized MCs using AMX, we observed a dosage-dependent decrease of MCs degranulation, indicating direct involvement of the FcɛRI in the degranulation process of BLA (Figure 2A).To investigate whether degranulation was mediated by IgE, we neutralized serum IgE by adding omalizumab before MC sensitisation. This showed no impact on the AMX induced degranulation (Figure 2A). In contrast, omalizumab inhibited MC degranulation in a classical IgE model, using pooled serum from cat allergic patients stimulated with cat allergen (Figure 2B).To determine whether FcεRI-specific IgG is functionally responsible for the AMX induced MCs degranulation, we isolated IgG from BLA serum using IgG-depletion spin columns. MCs sensitized with the IgG-only fraction showed no response to anti-IgE, but retained a strong response to AMX (Figure 2B). In comparison, in the IgG-depleted serum fraction (~60% IgG removed), we observed a strong degranulation to anti-IgE stimulation but a weakened response to AMX (Figure 2C).A limitation of this preliminary work is it used serum from only one BLA patient.In summary, we developed a cell model for BLA using in vitrodifferentiated human MCs. This BLA model has demonstrated the involvement of FcεRI-specific IgG in mediating AMX-induced MCs degranulation. The results are worthy of further investigation in a larger patient cohort.Word Count 599Figure legend ( Word count 98 and 98 respectively, max 100)Figure 1. Demonstration of in vitro BLA model using MCs derived from human progenitor cells. A) After washing the sensitized MCs with phosphate buffered saline (PBS), different cells responsiveness to AMX and anti-IgE. B) When adding the AMX in the presence of BL IDHR serum, cell degranulation was observed. C) No degranulation was observed from AMX stimulation when serum from a non-BL IDHR subject was used. D) Treatment of AMX in the absence of serum showed a mild increase of CD63 compared to cells without stimulation, Percentage CD63+ cells is shown in the box. Representative figures from three independent experiments.Figure 2. Investigating the role of FcεRI-specific IgG in BLAin vitro model A) the BLA in vitro model, B) classical type I IgE cat allergy model. AMX or cat allergen induced degranulation was quantified on MCs sensitized with single BLA or pooled cat allergic subject serum pre-treated with recombinant FcεRI alpha chain fragment or omalizumab. C) BLA in vitro model; MCs sensitized with either IgG-depleted serum fraction or IgG-only fraction. Sensitised MCs were stimulated with anti-IgE, AMX or media control. Histogram demonstrating fluorescence intensity of CD63 expression on MCs surface. Mean ±SD. *=p<0.05 from three independent experiments, NS=not significant.
- 11 January 2023
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 53 (3) , 378-379
Towards a safe and efficient de‐labelling penicillin allergy service by non‐allergists
- 11 January 2023
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 53 (3) , 378-379
Towards a safe and efficient de‐labelling penicillin allergy service by non‐allergists
- Open Access
- 16 November 2022
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 53 (4) , 405-416
Progenitor cell‐derived basophils: A novel barcoded passive degranulation assay in allergic diseases
Background: Effector cells assays provide an overall measure of responsiveness to allergen, but the lack of reliable and high‐throughput assays limits the clinical utility. We aimed to develop a high‐throughput basophil activation test based on human progenitor cell‐derived basophils (PCB) and investigate the role of PCB activation test (PCBAT) in allergic diseases.Methods: Progenitor cell‐derived basophils were differentiated from CD34+ progenitor cells and sensitized with sera from subjects sensitized to cat, peanut or atopic controls. Sensitized PCBs were stimulated with increasing concentrations of the corresponding allergens in vitro. Degranulation was assessed by measuring CD63 expression using flow cytometry. The correlations between PCBAT and clinical allergy were assessed.Results: Following passive sensitization of the mature PCBs with serum and allergen stimulation, an allergen specific dose‐dependent increase in CD63 expression was observed. Sera from subjects sensitized to cat (n = 35, of which 17 subjects had clinical reactivity quantified using inhaled allergen challenge), peanut allergic (n = 30, of which 15 subjects had clinical reactivity validated using double blind, placebo controlled food challenges [DBPCFC]), peanut‐sensitized but tolerant subjects (n = 5) were used to sensitize PCBs. PCBAT area under the curve (AUC) correlated with sIgE (r2 = .49, p = .001) in subjects sensitized to cat (sIgE ≥ 0.35KU/L). The provocation concentration of inhaled cat allergen (PC20) correlated with PCBAT AUC (r2 = .33, p = .016). In subjects sensitized to peanut, PCBAT AUC was highly correlated with sIgE to Ara h 2 (r2 = .59, p < .0001). Peanut threshold cumulative dose during DBPCFC was negatively correlated with PCBAT AUC (r2 = .57, p = .001) and IgE to Ara h1 (r2 = .55, p = .007), but not with sIgE to whole peanut or Ara h2. All peanut‐sensitized but tolerant subjects showed no reaction to peanut on PCBAT.Conclusion: Progenitor cell‐derived basophils activation test is a high‐throughput assay, which correlates with clinical allergy and may confer a powerful alternative tool in allergy testing.
- 16 November 2022
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 53 (4) , 405-416
Open AccessProgenitor cell‐derived basophils: A novel barcoded passive degranulation assay in allergic diseases
Background: Effector cells assays provide an overall measure of responsiveness to allergen, but the lack of reliable and high‐throughput assays limits the clinical utility. We aimed to develop a high‐throughput basophil activation test based on human progenitor cell‐derived basophils (PCB) and investigate the role of PCB activation test (PCBAT) in allergic diseases.Methods: Progenitor cell‐derived basophils were differentiated from CD34+ progenitor cells and sensitized with sera from subjects sensitized to cat, peanut or atopic controls. Sensitized PCBs were stimulated with increasing concentrations of the corresponding allergens in vitro. Degranulation was assessed by measuring CD63 expression using flow cytometry. The correlations between PCBAT and clinical allergy were assessed.Results: Following passive sensitization of the mature PCBs with serum and allergen stimulation, an allergen specific dose‐dependent increase in CD63 expression was observed. Sera from subjects sensitized to cat (n = 35, of which 17 subjects had clinical reactivity quantified using inhaled allergen challenge), peanut allergic (n = 30, of which 15 subjects had clinical reactivity validated using double blind, placebo controlled food challenges [DBPCFC]), peanut‐sensitized but tolerant subjects (n = 5) were used to sensitize PCBs. PCBAT area under the curve (AUC) correlated with sIgE (r2 = .49, p = .001) in subjects sensitized to cat (sIgE ≥ 0.35KU/L). The provocation concentration of inhaled cat allergen (PC20) correlated with PCBAT AUC (r2 = .33, p = .016). In subjects sensitized to peanut, PCBAT AUC was highly correlated with sIgE to Ara h 2 (r2 = .59, p < .0001). Peanut threshold cumulative dose during DBPCFC was negatively correlated with PCBAT AUC (r2 = .57, p = .001) and IgE to Ara h1 (r2 = .55, p = .007), but not with sIgE to whole peanut or Ara h2. All peanut‐sensitized but tolerant subjects showed no reaction to peanut on PCBAT.Conclusion: Progenitor cell‐derived basophils activation test is a high‐throughput assay, which correlates with clinical allergy and may confer a powerful alternative tool in allergy testing.
- Open Access
- 12 September 2022
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 8 (3)
Defining the normal range of fractional exhaled nitric oxide in children: one size does not fit all
Background: The normal range of fractional exhaled nitric oxide (FENO) is influenced by demographic factors. However, single, fixed cut-off values are used for clinical interpretation in children despite rapid growth. We aimed to define the normal range ofFENOduring childhood and evaluate its utility in a diagnostic setting.Method: FENOpercentile charts were developed using data from nonasthmatic children in a population-based birth cohort (Manchester Asthma and Allergy Study). Children were skin prick tested,FENOmeasured at the ages of 8, 11, 13–16 and 18 years and clinical information collected. This chart was externally validated in the Study of Eczema and Asthma to Observe the Influence of Nutrition (SEATON) cohort before being prospectively tested in symptomatic, treatment-naïve patients with suspected asthma in a diagnostic setting (Rapid Access Diagnostics for Asthma study).Results: Height, weight, body mass index and age were predictive ofFENOin univariate analysis using 1220FENOmeasurements. Only height remained significant after adjustment in the overall, nonatopic and atopic populations, and was included in the predictive equations for 50th, 75th 90th and 98th percentiles. The proposed percentile lines corresponded to the 57th (95% CI 53rd–61st), 80th (76th–83rd), 90th (87th–92nd) and 98th (96th–99th) percentiles in the SEATON cohort (660 measurements). When tested in 73 symptomatic treatment-naïve children and young adults (median (interquartile range) age: 11 (8–14) years), anFENO>90th percentile gave a 96% specificity and positive predictive value of 97%, identifying 59% of children who were subsequently diagnosed with asthma after extensive testing.Conclusion: We developed a height-basedFENOpercentile chart which quantifies the probability of asthma in symptomatic children and merits further validation towards clinical implementation.
- 12 September 2022
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 8 (3)
Open AccessDefining the normal range of fractional exhaled nitric oxide in children: one size does not fit all
Background: The normal range of fractional exhaled nitric oxide (FENO) is influenced by demographic factors. However, single, fixed cut-off values are used for clinical interpretation in children despite rapid growth. We aimed to define the normal range ofFENOduring childhood and evaluate its utility in a diagnostic setting.Method: FENOpercentile charts were developed using data from nonasthmatic children in a population-based birth cohort (Manchester Asthma and Allergy Study). Children were skin prick tested,FENOmeasured at the ages of 8, 11, 13–16 and 18 years and clinical information collected. This chart was externally validated in the Study of Eczema and Asthma to Observe the Influence of Nutrition (SEATON) cohort before being prospectively tested in symptomatic, treatment-naïve patients with suspected asthma in a diagnostic setting (Rapid Access Diagnostics for Asthma study).Results: Height, weight, body mass index and age were predictive ofFENOin univariate analysis using 1220FENOmeasurements. Only height remained significant after adjustment in the overall, nonatopic and atopic populations, and was included in the predictive equations for 50th, 75th 90th and 98th percentiles. The proposed percentile lines corresponded to the 57th (95% CI 53rd–61st), 80th (76th–83rd), 90th (87th–92nd) and 98th (96th–99th) percentiles in the SEATON cohort (660 measurements). When tested in 73 symptomatic treatment-naïve children and young adults (median (interquartile range) age: 11 (8–14) years), anFENO>90th percentile gave a 96% specificity and positive predictive value of 97%, identifying 59% of children who were subsequently diagnosed with asthma after extensive testing.Conclusion: We developed a height-basedFENOpercentile chart which quantifies the probability of asthma in symptomatic children and merits further validation towards clinical implementation.
- Open Access
- 17 November 2021
- Published by Springer Nature in Cureus
- Vol. 13 (11) , e19675
A Case of Life-Threatening Airway Obstruction Caused by Acute Diphtheria Infection in the United Kingdom
Diphtheria is a highly contagious and potentially life-threatening infection. Cases in the United Kingdom are rare due to widespread vaccination. However, in recent years, there has been a notable increase in cases in the United Kingdom. We present the case of a 76-year-old British Caucasian female who presented to the Emergency Department with shortness of breath and "chest tightness." She reported a five-day history of worsening sore throat, odynophagia, and aphonia. On inspection, she had noisy, laboured breathing with the use of her accessory muscles. Flexible laryngoscopy revealed purulent, thick yellow discharge in the nasal cavity, oropharynx, and supraglottis, with oedema of the subglottic mucosa. She became increasingly breathless and was peri-arrest when emergency orotracheal intubation was performed. She was transferred to the Intensive Care Unit for ventilatory support and intravenous antibiotics. Four days after presentation, her microbiology results confirmed toxigenic Corynebacterium ulcerans. Public Health England was informed immediately. The patient was isolated and contact tracing was commenced. Thirty staff members were required to self-isolate and take prophylactic antibiotics due to close patient contact. It was particularly noteworthy that our patient was a UK national with no recent history of foreign travel. This case demonstrates the importance of remaining vigilant to atypical causes of airway obstruction secondary to infection. Early suspicion and prompt patient isolation may prevent community and occupational transmission and minimise the impact of contact tracing on hospital staffing. Migration from endemic countries and declining childhood vaccination rates may lead to a further rise in UK cases of diphtheria in the future.
- 17 November 2021
- Published by Springer Nature in Cureus
- Vol. 13 (11) , e19675
Open AccessA Case of Life-Threatening Airway Obstruction Caused by Acute Diphtheria Infection in the United Kingdom
Diphtheria is a highly contagious and potentially life-threatening infection. Cases in the United Kingdom are rare due to widespread vaccination. However, in recent years, there has been a notable increase in cases in the United Kingdom. We present the case of a 76-year-old British Caucasian female who presented to the Emergency Department with shortness of breath and "chest tightness." She reported a five-day history of worsening sore throat, odynophagia, and aphonia. On inspection, she had noisy, laboured breathing with the use of her accessory muscles. Flexible laryngoscopy revealed purulent, thick yellow discharge in the nasal cavity, oropharynx, and supraglottis, with oedema of the subglottic mucosa. She became increasingly breathless and was peri-arrest when emergency orotracheal intubation was performed. She was transferred to the Intensive Care Unit for ventilatory support and intravenous antibiotics. Four days after presentation, her microbiology results confirmed toxigenic Corynebacterium ulcerans. Public Health England was informed immediately. The patient was isolated and contact tracing was commenced. Thirty staff members were required to self-isolate and take prophylactic antibiotics due to close patient contact. It was particularly noteworthy that our patient was a UK national with no recent history of foreign travel. This case demonstrates the importance of remaining vigilant to atypical causes of airway obstruction secondary to infection. Early suspicion and prompt patient isolation may prevent community and occupational transmission and minimise the impact of contact tracing on hospital staffing. Migration from endemic countries and declining childhood vaccination rates may lead to a further rise in UK cases of diphtheria in the future.